OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Cell International is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment	361
New insights into M1/M2 macrophages: key modulators in cancer progression	248
p53 signaling in cancer progression and therapy	228
Challenges of applying multicellular tumor spheroids in preclinical phase	216
Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine	198
Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment	167
Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future	151
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier	115
The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers	107
Potential mechanisms of quercetin in cancer prevention: focus on cellular and molecular targets	95
RRM2 protects against ferroptosis and is a tumor biomarker for liver cancer	92
Dynamic regulation and functions of mRNA m6A modification	85
Ninjurin 2 rs118050317 gene polymorphism and endometrial cancer risk	84
Polyamines and related signaling pathways in cancer	79
Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures	76
Integrated single-cell and bulk RNA sequencing analysis identifies a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in colorectal cancer	74
METTL3 promotes lung adenocarcinoma tumor growth and inhibits ferroptosis by stabilizing SLC7A11 m6A modification	72
Identification the ferroptosis-related gene signature in patients with esophageal adenocarcinoma	72
Recent advances and limitations of mTOR inhibitors in the treatment of cancer	70
Tumor-associated macrophage derived IL-6 enriches cancer stem cell population and promotes breast tumor progression via Stat-3 pathway	69
Emerging roles of RNA methylation in gastrointestinal cancers	69
Induction and application of ferroptosis in cancer therapy	67
SCUBE3 downregulation modulates hepatocellular carcinoma by inhibiting CCNE1 via TGFβ/PI3K/AKT/GSK3β pathway	60
The biological function of m6A reader YTHDF2 and its role in human disease	58
Characterization of a ferroptosis and iron-metabolism related lncRNA signature in lung adenocarcinoma	56

Musashi-1 promotes cancer stem cell properties of glioblastoma cells via upregulation of YTHDF1	55
Triple-negative breast cancer: understanding Wnt signaling in drug resistance	55
FTH promotes the proliferation and renders the HCC cells specifically resist to ferroptosis by maintaining iron homeostasis	55
The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition, migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis	54
Mesenchymal stem cells in cancer progression and anticancer therapeutic resistance	54
Exosome-transferred hsa_circ_0014235 promotes DDP chemoresistance and deteriorates the development of non-small cell lung cancer by mediating the miR-520a-5p/CDK4 pathway	54
Exosomal lncRNA SNHG10 derived from colorectal cancer cells suppresses natural killer cell cytotoxicity by upregulating INHBC	53
CAR-T cell combination therapy: the next revolution in cancer treatment	53
Apigenin role as cell-signaling pathways modulator: implications in cancer prevention and treatment	52
Recent advances in non-small cell lung cancer targeted therapy; an update review	52
Potential of antibody–drug conjugates (ADCs) for cancer therapy	51
Myricetin: targeting signaling networks in cancer and its implication in chemotherapy	51
Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired	51
Morphological and molecular characteristics of spheroid formation in HT-29 and Caco-2 colorectal cancer cell lines	50
Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma	50
Anti-tumor activity of resveratrol against gastric cancer: a review of recent advances with an emphasis on molecular pathways	49
Cancer-related circular RNA: diverse biological functions	48
An updated review of mechanistic potentials of melatonin against cancer: pivotal roles in angiogenesis, apoptosis, autophagy, endoplasmic reticulum stress and oxidative stress	48
Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin	45
Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches	45
Strategies to overcome the main challenges of the use of exosomes as drug carrier for cancer therapy	45
Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review	45